Tubulis Raises €10.7 M Series A to Advance Development of a New Generation of Antibody-Drug Conjugates
Tubulis Raises €10.7 M Series A to Advance Development of a New Generation of Antibody-Drug Conjugates
07/21/20, 9:10 AM
Location
munichMoney raised
€10 million
Industry
biotechnology research
health care
Round Type
series a
Tubulis today announced the close of a €10.7 million Series A financing round to accelerate the development of a new class of highly stable and efficient antibody-drug conjugates (ADCs) and to support the further growth of the company. The financing round was co-led by BioMedPartners and High-Tech Gründerfonds (HTGF) with support from Seventure Partners, coparion, Bayern Kapital, and OCCIDENT alongside significant contributions by high net worth individuals and the founders. Tubulis was spun out in 2019 from the Leibniz Research Institute in Berlin (FMP) and the Ludwig Maximilians University (LMU) in Munich with the aim of expanding the therapeutic potential of ADCs for cancer and other disease indications.
Company Info
Location
munich, bavaria, germany
Additional Info
Tubulis® generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. We will advance a range of conjugates, unlimited by indication, using our own discovery capabilities and by solving development challenges for partners with both antibody and chemical assets.